Top

Published in:

01-01-2011 | Preclinical study

Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells

Authors: Hyun Chang, Hei-Cheul Jeung, Je Jun Jung, Tae Soo Kim, Sun Young Rha, Hyun Cheol Chung

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Abstract

Here we evaluated the cytotoxic effects of a combination of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) and taxanes in human breast cancer cell lines. Combination treatment with taxane and SAHA had a synergistic cytotoxic effect against taxane-resistant breast cancer cells. Oligonucleotide microarray analysis identified 28 genes (MAPK13, ATP2C1, ANKRD57, MT1G, RGL4, C12orf49, EXOC6, RAB4A, TM9SF3, IFNGR1, DMD, HCG9, KIFC3, SYNGR3, NDRG4, NT5E, EOMES, SMC4, LANCL1, SCHIP1, and 8 ESTs) whose expression correlated with the combined effect of paclitaxel and SAHA. Twelve of these genes were down-regulated in cell lines that were paclitaxel-resistant but combination synergistic. SAHA induced NT5E mRNA expression in paclitaxel-resistant YCC-B1 cell. Our results indicate that a combination of taxane and SAHA could be efficacious for the treatment of breast cancer and that genes involved in the synergistic response to paclitaxel and SAHA could serve as biomarkers to predict therapeutic response in breast cancer patients.

Available only for authorised users

Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM (2005) Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542–5551CrossRefPubMed

Eniu A, Palmieri FM, Perez EA (2005) Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 10:665–685CrossRefPubMed

Yardley DA (2008) Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes. Clin Breast Cancer 8:487–492CrossRefPubMed

Chang H, Rha SY, Jeung HC, Im CK, Ahn JB, Kwon WS, Yoo NC, Roh JK, Chung HC (2009) Association of the ABCB1 gene polymorphisms 2677G > T/A and 3435C > T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 20:272–277CrossRefPubMed

Goel S, Abdi E, Lewis CR, Links M, Begbie S, Clingan P, Ganju V, Beith J (2009) Phase II study of gemcitabine and docetaxel in combination for the treatment of metastatic breast cancer. Asia Pac J Clin Oncol 5:32–38CrossRef

Carew JS, Giles FJ, Nawrocki ST (2008) Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269:7–17CrossRefPubMed

Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 1:194–202CrossRefPubMed

Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51CrossRefPubMed

Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26:5541–5552CrossRefPubMed

10.

Marks PA, Breslow R (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25:84–90CrossRefPubMed

11.

Bots M, Johnstone RW (2009) Rational combinations using HDAC inhibitors. Clin Cancer Res 15:3970–3977CrossRefPubMed

12.

Luu TH, Morgan RJ, Leong L, Lim D, McNamara M, Portnow J, Frankel P, Smith DD, Doroshow JH, Wong C, Aparicio A, Gandara DR, Somlo G (2008) A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res 14:7138–7142CrossRefPubMed

13.

Carraway HE, Gore SD (2007) Addition of histone deacetylase inhibitors in combination therapy. J Clin Oncol 25:1955–1956CrossRefPubMed

14.

Nolan L, Johnson PW, Ganesan A, Packham G, Crabb SJ (2008) Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer 99:689–694CrossRefPubMed

15.

Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, Balasis M, Rocha K, Wang HG, Richon V, Bhalla K (2005) Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin Cancer Res 11:6382–6389CrossRefPubMed

16.

Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, Wang HG, Atadja P, Bhalla K (2003) Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther 2:971–984PubMed

17.

Kim TM, Jeong HJ, Seo MY, Kim SC, Cho G, Park CH, Kim TS, Park KH, Chung HC, Rha SY (2005) Determination of genes related to gastrointestinal tract origin cancer cells using a cDNA microarray. Clin Cancer Res 11:79–86PubMed

18.

Kwon WS, Rha SY, Choi YH, Lee JO, Park KH, Jung JJ, Kim TS, Jeung HC, Chung HC (2006) Ribonucleotide reductase M1 (RRM1) 2464G > A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines. Pharmacogenet Genomics 16:429–438CrossRefPubMed

19.

Kwon WS, Rha SY, Jeung HC, Ahn JB, Jung JJ, Noh SH, Chung HC (2009) G-T haplotype (2677G > T/A and 3435C > T) of ABCB1 gene polymorphisms is associated with ethnic differences to paclitaxel sensitivity in cancer cells with different gene expression pattern. Cancer Lett 277:155–163CrossRefPubMed

20.

Kim DH, Lee J, Kim KN, Kim HJ, Jeung HC, Chung HC, Kwon HJ (2007) Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun 356:233–238CrossRefPubMed

21.

Jung JJ, Jeung HC, Chung HC, Lee JO, Kim TS, Kim YT, Noh SH, Rha SY (2009) In vitro pharmacogenomic database and chemosensitivity predictive genes in gastric cancer. Genomics 93:52–61CrossRefPubMed

22.

Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27–55CrossRefPubMed

23.

Schrump DS (2009) Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 15:3947–3957CrossRefPubMed

24.

Miyanaga A, Gemma A, Noro R, Kataoka K, Matsuda K, Nara M, Okano T, Seike M, Yoshimura A, Kawakami A, Uesaka H, Nakae H, Kudoh S (2008) Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 7:1923–1930CrossRefPubMed

25.

Dejligbjerg M, Grauslund M, Christensen IJ, Tjornelund J, Buhl Jensen P, Sehested M (2008) Identification of predictive biomarkers for the histone deacetylase inhibitor belinostat in a panel of human cancer cell lines. Cancer Biomark 4:101–109PubMed

26.

Sasakawa Y, Naoe Y, Sogo N, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S (2005) Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol 69:603–616CrossRefPubMed

27.

Schindler EM, Hindes A, Gribben EL, Burns CJ, Yin Y, Lin MH, Owen RJ, Longmore GD, Kissling GE, Arthur JS, Efimova T (2009) p38delta Mitogen-activated protein kinase is essential for skin tumor development in mice. Cancer Res 69:4648–4655CrossRefPubMed

28.

Li-Sher FT, Ooi A, Huang D, Wong JC, Qian CN, Chao C, Ooi L, Tan YM, Chung A, Cheow PC, Zhang Z, Petillo D, Yang XJ, Teh BT (2009) p38delta/MAPK13 as a diagnostic marker for cholangiocarcinoma and its involvement in cell motility and invasion. Int J Cancer (in press)

29.

Ferrario C, Lavagni P, Gariboldi M, Miranda C, Losa M, Cleris L, Formelli F, Pilotti S, Pierotti MA, Greco A (2008) Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Lab Invest 88:474–481CrossRefPubMed

30.

Wang Y, Liu D, Chen P, Koeffler HP, Tong X, Xie D (2008) Negative feedback regulation of IFN-gamma pathway by IFN regulatory factor 2 in esophageal cancers. Cancer Res 68:1136–1143CrossRefPubMed

31.

Wang L, Zhou X, Zhou T, Ma D, Chen S, Zhi X, Yin L, Shao Z, Ou Z, Zhou P (2008) Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol 134:365–372CrossRefPubMed

32.

Ujházy P, Berleth ES, Pietkiewicz JM, Kitano H, Skaar JR, Ehrke MJ, Mihich E (1996) Evidence for the involvement of ecto-5′-nucleotidase (CD73) in drug resistance. Int J Cancer 68:493–500CrossRefPubMed

33.

Ellis L, Pan Y, Smyth GK, George DJ, McCormack C, Williams-Truax R, Mita M, Beck J, Burris H, Ryan G, Atadja P, Butterfoss D, Dugan M, Culver K, Johnstone RW, Prince HM (2008) Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res 14:4500–4510CrossRefPubMed

Title: Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells
Authors: Hyun Chang
Hei-Cheul Jeung
Je Jun Jung
Tae Soo Kim
Sun Young Rha
Hyun Cheol Chung
Publication date: 01-01-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-0825-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Associations between mammographic density and serum and dietary cholesterol

The association of SULT1A1 codon 213 polymorphism and breast cancer susceptibility: meta-analysis from 16 studies involving 23,445 subjects

Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials

No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families

Lack of an association between AURKA T91A polymorphisms and breast cancer: a meta-analysis involving 32,141 subjects

PKA-induced phosphorylation of ERα at serine 305 and high PAK1 levels is associated with sensitivity to tamoxifen in ER-positive breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer